AX-2025-020863 · MK-677 (Ibutamoren mesylate) · CPC lot CPC-2503-G2382

Section 1

Results

Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.53	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.47	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — sulfonamide hydrolysis product (+18 Da)	0.90	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	624.2181	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	624.2206	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+4.0	ppm	± 10	PASS
Total peptide content	by difference from the gravimetric mass balance	77.98	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	76.83	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	634.53	mg	500 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	487.509	mg	500 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	97.5	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	5.54	%	≤ 10.0	PASS
Counter-ion (mesylate)	anion-exchange ion chromatography	15.84	%	≤ 12.0	FAIL
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.64	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.34	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.11	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	14.00	min	13.86 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.04	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	53,928	—	≥ 20,000	PASS
Resolution to nearest impurity	vs free base (des-mesylate, −96 Da)	0.16	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 53,928, and skew follows the reported asymmetry factor of 1.04. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.90 % impurity against a 98.53 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	MK-677 (Ibutamoren mesylate) — main peak	14.00	4,788,863	98.53	—
2	sulfonamide hydrolysis product (+18 Da)	13.14	43,743	0.90	+18.011
3	free base (des-mesylate, −96 Da)	14.04	17,497	0.36	-96.011
4	spiroindane regioisomer	14.44	4,374	0.09	0.000
5	residual DMF (process solvent)	5.80	3,402	0.07	-551.000
6	O-desmethyl metabolite analogue (−14 Da)	13.48	2,430	0.05	-14.016
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 624.2181 Da, computed from C27H36N4O5S · CH4O3S. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 624.2206 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	313.1163	313.1176	0.0013	56.3
1+	625.2254	625.2279	0.0025	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	5.54
Counter-ion (mesylate)	ion chromatography	15.84
Residual solvent + inorganic residue	estimated	0.64
Total peptide content	by difference	77.98
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.53	98.53	divergence -0.22 pp vs batch median
Total impurities (% area)	1.47	1.47
Largest single impurity (% area)	not stated	0.90
Water (%)	5.1	5.54
Counter-ion (%)	not stated	15.84
Peptide content (%w/w)	90.1	77.98
Endotoxin (EU/mg)	0.21	0.34
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 6 d) → laboratory (hand-carried, 6 d) → assay.
Assay date: 02 Jun 2025
Submitted to the index: 24 Jun 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

esi_tof24 Jun 2025

The observed monoisotopic mass on this record reconciles with the theoretical value to four decimal places, which is the arithmetic the index re-derives in its own build check rather than accepting from the report.

shipping_temp24 Jun 2025

The custody block above records the shipping conditions this vial actually experienced, which is the condition an ordinary buyer's vial experiences too. That representativeness is the point.

hplc_ola24 Jun 2025

A longer gradient buys resolution on close-eluting pairs at a linear cost in run time. Janoshik ran 30 min here; the reference method runs 30, and the difference is visible in this figure.

Contributor #G-886924 Jun 2025

Purity 98.53 % with sulfonamide hydrolysis product (+18 Da) at 0.90 % nearby. Read the pair together: the purity figure and its nearest neighbour are two views of one integration decision.

Section 7

Related records

Same batch — lot CPC-2503-G2382 n=7

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-020860	CPC-2503-G2382	Janoshik	2025-Q2	98.75	5.28	91.0	Buyer-sourced	1	FAIL
AX-2025-020861	CPC-2503-G2382	Janoshik	2025-Q2	98.85	5.55	—	Buyer-sourced	1	FAIL
AX-2025-020862	CPC-2503-G2382	Medutest	2025-Q2	98.56	5.37	93.9	Buyer-sourced	1	FAIL
AX-2025-020864	CPC-2503-G2382	PeptideMeter	2025-Q2	98.66	5.17	93.8	Buyer-sourced	1	FAIL
AX-2025-020865	CPC-2503-G2382	Janoshik	2025-Q2	98.89	5.08	—	Buyer-sourced	1	FAIL
AX-2025-020866	CPC-2503-G2382	Janoshik	2025-Q2	98.78	5.55	—	Buyer-sourced	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

All MK-677 (Ibutamoren mesylate) records n=143
All CPC records n=227
All Janoshik records n=2989
All 2025-Q2 records n=619
MK-677 (Ibutamoren mesylate) by supplier
MK-677 (Ibutamoren mesylate) impurity profile

Other recent MK-677 (Ibutamoren mesylate) records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041633	FGP	FGP-2604-K8509	PeptideMeter	2026-Q2	99.81	4.91	96.2	Buyer-sourced	0	FAIL
AX-2026-041733	TFS	TFS-{CAT}-1096	PeptideMeter	2026-Q2	99.07	3.93	95.1	Laboratory-retained	0	FAIL
AX-2026-043468	BCH	BCH-2511-G5204	Medutest	2026-Q2	98.85	4.30	96.5	Buyer-sourced	1	FAIL
AX-2026-042647	SWB	SWB-2605-B7365	Nordanalyt	2026-Q2	99.28	2.86	93.1	Buyer-sourced	0	FAIL
AX-2026-041634	FGP	FGP-2604-K8509	PeptideMeter	2026-Q2	99.86	5.17	—	Buyer-sourced	0	FAIL
AX-2026-043469	BCH	BCH-2511-G5204	Medutest	2026-Q2	98.51	4.86	—	Buyer-sourced	1	FAIL
AX-2026-042648	SWB	SWB-2605-B7365	Janoshik	2026-Q2	99.93	2.60	96.9	Supplier-supplied	0	FAIL
AX-2026-041732	TFS	TFS-{CAT}-1096	Janoshik	2026-Q2	99.48	3.16	106.4	Buyer-sourced	0	FAIL

Other recent CPC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043319	BPC-157	CPC-2602-W1610	Medutest	2026-Q3	98.82	2.88	103.5	Buyer-sourced	2	MARGINAL
AX-2026-043295	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.34	5.17	106.3	Buyer-sourced	0	FAIL
AX-2026-043288	Tirzepatide	CPC-2607-L1516	Janoshik	2026-Q3	96.89	5.11	101.1	Laboratory-retained	0	FAIL
AX-2026-043327	N-Acetyl Semax Amide	CPC-2602-D1905	Nordanalyt	2026-Q3	99.05	5.67	90.6	Buyer-sourced	1	FAIL
AX-2026-043328	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.49	6.83	100.9	Supplier-supplied	0	PASS
AX-2026-043257	L-Carnosine	CPC-2603-G9615	VendorInvestigate	2026-Q3	98.20	10.41	102.2	Buyer-sourced	0	FAIL
AX-2026-043297	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.01	4.95	103.5	Buyer-sourced	0	FAIL
AX-2026-043331	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.46	6.22	—	Supplier-supplied	0	PASS